Both benzodiazepines and non-benzodiazepines (commonly known as Z-drugs) have sedative effects and are regularly prescribed to Alzheimer’s patients. To assess a potential link between the drugs and the development of pneumonia, researchers examined information on 49,484 adults diagnosed with Alzheimer’s between 2005 and 2011 in Finland compiled in national databases. Among the patients, 5,232 were taking benzodiazepines and 3,269 were taking Z-drugs.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
While researchers identified no statistically significant relationship between Z-drugs and pneumonia, benzodiazepines were associated with a 30 percent increased risk of contracting pneumonia when compared to Alzheimer’s patients not taking the drug.
“Benefits and risks of the use of benzodiazepines should be carefully considered for patients with
Alzheimer disease and include risk of pneumonia,” concluded the study’s authors. “Accumulating evidence that use of benzodiazepines and Z-drugs is associated with respiratory adverse effects suggests that future studies examine the possible pharmacologic mechanisms.”
More articles on infection control:
Top 10 infection control stories, April 3-7
Dead bat found in packaged salad — CDC investigates rabies risk
Influenza B now the dominant strain as flu activity declines
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.